Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $556.25 million. The enterprise value is $1.41 billion.
| Market Cap | 556.25M |
| Enterprise Value | 1.41B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 113.06 million shares outstanding. The number of shares has decreased by -2.39% in one year.
| Current Share Class | 113.06M |
| Shares Outstanding | 113.06M |
| Shares Change (YoY) | -2.39% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 84.70% |
| Float | 94.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 14.07 |
| PS Ratio | 0.27 |
| Forward PS | 0.18 |
| PB Ratio | 1.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.00 |
| P/OCF Ratio | 10.37 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.23, with an EV/FCF ratio of 17.64.
| EV / Earnings | n/a |
| EV / Sales | 0.68 |
| EV / EBITDA | 23.23 |
| EV / EBIT | n/a |
| EV / FCF | 17.64 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 2.53.
| Current Ratio | 1.24 |
| Quick Ratio | 1.15 |
| Debt / Equity | 2.53 |
| Debt / EBITDA | 14.99 |
| Debt / FCF | 12.07 |
| Interest Coverage | -0.40 |
Financial Efficiency
Return on equity (ROE) is -66.97% and return on invested capital (ROIC) is -2.25%.
| Return on Equity (ROE) | -66.97% |
| Return on Assets (ROA) | -0.78% |
| Return on Invested Capital (ROIC) | -2.25% |
| Return on Capital Employed (ROCE) | -1.88% |
| Weighted Average Cost of Capital (WACC) | 6.71% |
| Revenue Per Employee | $499,290 |
| Profits Per Employee | -$121,680 |
| Employee Count | 4,200 |
| Asset Turnover | 0.95 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Evolent Health has paid $2.85 million in taxes.
| Income Tax | 2.85M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.28% in the last 52 weeks. The beta is 0.78, so Evolent Health's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -49.28% |
| 50-Day Moving Average | 4.77 |
| 200-Day Moving Average | 3.86 |
| Relative Strength Index (RSI) | 60.54 |
| Average Volume (20 Days) | 3,400,056 |
Short Selling Information
The latest short interest is 15.81 million, so 13.99% of the outstanding shares have been sold short.
| Short Interest | 15.81M |
| Short Previous Month | 15.83M |
| Short % of Shares Out | 13.99% |
| Short % of Float | 16.80% |
| Short Ratio (days to cover) | 4.72 |
Income Statement
In the last 12 months, Evolent Health had revenue of $2.10 billion and -$511.06 million in losses. Loss per share was -$4.54.
| Revenue | 2.10B |
| Gross Profit | 361.64M |
| Operating Income | -27.84M |
| Pretax Income | -502.14M |
| Net Income | -511.06M |
| EBITDA | 61.04M |
| EBIT | -27.84M |
| Loss Per Share | -$4.54 |
Balance Sheet
The company has $115.70 million in cash and $970.43 million in debt, with a net cash position of -$854.73 million or -$7.56 per share.
| Cash & Cash Equivalents | 115.70M |
| Total Debt | 970.43M |
| Net Cash | -854.73M |
| Net Cash Per Share | -$7.56 |
| Equity (Book Value) | 383.22M |
| Book Value Per Share | 3.40 |
| Working Capital | 117.68M |
Cash Flow
In the last 12 months, operating cash flow was $54.32 million and capital expenditures $26.07 million, giving a free cash flow of $80.39 million.
| Operating Cash Flow | 54.32M |
| Capital Expenditures | 26.07M |
| Depreciation & Amortization | 88.87M |
| Net Borrowing | -103.44M |
| Free Cash Flow | 80.39M |
| FCF Per Share | $0.71 |
Margins
Gross margin is 17.25%, with operating and profit margins of -1.33% and -24.08%.
| Gross Margin | 17.25% |
| Operating Margin | -1.33% |
| Pretax Margin | -23.95% |
| Profit Margin | -24.08% |
| EBITDA Margin | 2.91% |
| EBIT Margin | -1.33% |
| FCF Margin | 3.83% |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.39% |
| Shareholder Yield | 2.39% |
| Earnings Yield | -90.77% |
| FCF Yield | 14.28% |
Analyst Forecast
The average price target for Evolent Health is $5.77, which is 17.28% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.77 |
| Price Target Difference | 17.28% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 25.06% |
| EPS Growth Forecast (3Y) | 80.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 0.36 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.36 |
| Piotroski F-Score | 5 |